Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senior CDER Management Panel Could Facilitate Novel Therapy Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

CDER Director Janet Woodcock is creating an executive-level forum to deliberate medical policies, including those needed to smooth drug reviews. She envisions stakeholder input on topics for discussion by the panel.


Related Content

FDA’s Breakthrough Products: Could Patients Drive The Designations?
CDER Policy Council Urged To Address Manufacturer/Payer Communications
CDER Medical Policy Council Balances “Breakthrough” Requests With Broader Issues
CDER Is Stressing Consistency As It Rolls Out FDASIA Programs
FDA’s Jenkins On “Progressive Approval”: Don’t Lower The Efficacy Bar
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
BIO's "Big Ideas" Include Expanding FDA's Mission, Allowing "Progressive Approval"





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts